2024 | Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma | Sangro, B; Chan, S L; Kelley, R K; Lau, G; Kudo, M; Sukeepaisarnjaroen, W; Yarchoan, M; De Toni, E N; Furuse, J; Kang, Y K; Galle, P R; Rimassa, L; Heurgué, A; Tam, V C; Van Dao, T; Thungappa, S C; Breder, V; Ostapenko, Y; Reig, M; Makowsky, M; Paskow, M J; Gupta, C; Kurland, J F; Negro, A; Abou-Alfa, G K; ANN-LII CHENG | Annals of oncology : official journal of the European Society for Medical Oncology | | | |
2024 | Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 | El-Khoueiry, A B; Trojan, J; Meyer, T; Yau, T; Melero, I; Kudo, M; CHIUN HSU ; Kim, T-Y; Choo, S-P; Kang, Y-K; Yeo, W; Chopra, A; Soleymani, S; Yao, J; Neely, J; Tschaika, M; Welling, T H; Sangro, B | Annals of oncology : official journal of the European Society for Medical Oncology | 1 | | |